able to bind diverse MHC-II alleles to ease immune status monitoring and immunotherapies. Here, we review the current status of TERT biology, TERT/MHC-II immunobiology, and past and current vaccine clinical trials. We propose that monitoring CD4 T cell immunity against TERT is a simple and direct way to assess immune surveillance in cancer patients and a new way to predict
oftenassociatedwithslowrates ofsoil gineralization (Palansooriya et al., 2020;Xu et al., 2016). The alphadiversityof soilgicrotialcoggunitiesinditerenttreatgentgroupswasestigatedtased